Ensho Therapeutics
Morris Plains, US · Founded 2024 · Delaware corporation · 1 known investors
Founders & leadership
EW
Emily WengExecutive
BK
Bittoo KanwarExecutive
JA
James Andrew WhitneyExecutive
NB
Neena Bitritto-GargExecutive
MM
Matthew McKevittExecutive
Investors · 1
Reported raises · per SEC filings
Form D private placements$27.9M disclosed across 3 of 4 rounds · 2024–2026
▶$20MofferedFeb 2026 · 9 investors · BiotechnologyRule 506(b)
▶$20MofferedFeb 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carlos SolorzanoDirector
- Danielle FryExecutive Officer
- Gerhard HagnExecutive Officer
- Eric PhamDirector
- Arash RassoulpourDirector
- Offering amount
- $20M
- Minimum investment
- $1
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$22.5MraisedSep 2025 · 2 investors · BiotechnologyRule 506(b)
▶$22.5MraisedSep 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neena Bitritto-GargExecutive Officer, Director, Promoter
- Emily WengExecutive Officer
- Eric PhamDirector
- Matthew McKevittExecutive Officer
- Arash RassoulpourDirector
- Carlos SolorzanoDirector
- James WhitneyExecutive Officer
- Danielle FryExecutive Officer
- Bittoo KanwarExecutive Officer
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- Proceeds to insiders
- $1M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$5MraisedNov 2024 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Danielle FryExecutive Officer
- Matthew McKevittExecutive Officer
- Neena Bitritto-GargExecutive Officer, Director, Promoter
- James Andrew WhitneyExecutive Officer
- Emily WengExecutive Officer
- Bittoo KanwarExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $5M
- Proceeds to insiders
- $500K
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
▶$400KraisedAug 2024 · 2 investors · BiotechnologyRule 506(b)
▶$400KraisedAug 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Emily WengExecutive Officer
- Bittoo KanwarExecutive Officer
- James Andrew WhitneyExecutive Officer
- Neena Bitritto-GargExecutive Officer, Director, Promoter
- Matthew McKevittExecutive Officer
- Offering amount
- $2M
- Amount sold
- $400K
- Proceeds to insiders
- $500K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Ensho Therapeutics's investors?
- Ensho Therapeutics's investors include Global BioAccess Fund.
- How much funding has Ensho Therapeutics raised?
- Ensho Therapeutics has disclosed $27.9M raised across 3 of its 4 known rounds.
- Where is Ensho Therapeutics headquartered?
- Ensho Therapeutics is headquartered in Morris Plains, US.